DeepMed Research

The Sidney Kimmel Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.hopkinsmedicine.org/kimmel_cancer_center

Clinical Trials

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Phase 2

Recruiting

Conditions: MSI-H Tumors
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy

Interventions: Drug: Nivolumab
Drug: Relatlimab

First Posted Date: 2018-07-31

Last Posted Date: 2024-10-23

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 42

Registration Number: NCT03607890

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer

Not Applicable

Active, not recruiting

Conditions: Non-small Cell Lung Cancer Stage I

Interventions: Diagnostic Test: Post-SABR Biopsy

First Posted Date: 2018-07-27

Last Posted Date: 2025-03-18

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 6

Registration Number: NCT03603002

Locations: 🇺🇸
Bayview Medical Center, Baltimore, Maryland, United States

A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

Terminated

Conditions: BRAF V600E
Glioma
Pleomorphic Xantho-Astrocytoma
Glioblastoma

Interventions: Procedure: Surgical Cohort

First Posted Date: 2018-07-20

Last Posted Date: 2023-10-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 3

Registration Number: NCT03593993

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Massachusettes General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 2 locations

Combined Technology Enhanced Home Exercise Program and Other Non-pharmacological Intervention for Cancer Survivors

Not Applicable

Completed

Conditions: Acupressure
Exercise
Cancer-related Problem/Condition

Interventions: Behavioral: Technology Enhanced Home Exercise (TEHE)
Behavioral: Mindfulness body scan (MBI)
Behavioral: Auricular Point Acupressure (APA)

First Posted Date: 2018-07-03

Last Posted Date: 2025-04-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 100

Registration Number: NCT03576274

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Avelumab
Drug: Endocrine therapy
Drug: Palbociclib

First Posted Date: 2018-06-29

Last Posted Date: 2025-03-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 33

Registration Number: NCT03573648

Locations: 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 1 locations

COMbination of Bipolar Androgen Therapy and Nivolumab

Phase 2

Completed

Conditions: Prostate Cancer
Castration-resistant Prostate Cancer
Metastatic Prostate Cancer

Interventions: Drug: Testosterone cypionate
Drug: Nivolumab

First Posted Date: 2018-06-13

Last Posted Date: 2024-02-20

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 45

Registration Number: NCT03554317

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET

Phase 1

Completed

Conditions: Malignant Tumors
Schwannomas

Interventions: Drug: 18F-DCFPyL Injection

First Posted Date: 2018-05-31

Last Posted Date: 2023-01-11

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 38

Registration Number: NCT03542773

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Cancer, Obesity/Overweight and Insomnia Study

Not Applicable

Completed

Conditions: Overweight and Obesity
Insomnia
Breast Cancer

Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia
Behavioral: Sleep Education

First Posted Date: 2018-05-31

Last Posted Date: 2020-12-16

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 30

Registration Number: NCT03542604

Locations: 🇺🇸
Johns Hopkins University, Bayview Medical Campus, Baltimore, Maryland, United States

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Pancreatic Neoplasms
Digestive System Neoplasm
Adenocarcinoma
Pancreatic Diseases
Neoplasm, Glandular
Neoplasms Pancreatic
Digestive System Disease

Interventions: Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Capecitabine
Drug: Cisplatin
Drug: Irinotecan

First Posted Date: 2018-05-24

Last Posted Date: 2024-12-31

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 48

Registration Number: NCT03535727

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Muscadine Plus (MPX) In Men With Prostate Cancer

Phase 3

Terminated

Conditions: Adenocarcinoma of the Prostate

Interventions: Drug: Placebos
Drug: Muscadine Plus

First Posted Date: 2018-05-24

Last Posted Date: 2023-05-22

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 59

Registration Number: NCT03535675

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy